Ziad U. Khan, M.D.
- Medical Oncology
“I support my patients throughout the treatment process and respect the significance of the special, almost sacrosanct, relationship oncologists share with their patients.”
From the start, Ziad Khan, M.D., knew he wanted to be the kind of physician who bonds with his patients. Born and raised in Southern California, he traveled to Pakistan for medical school where he graduated at the top of his class. Shortly after graduating from medical school, he became both a caregiver and advocate for his mother, who was his first patient, when she was diagnosed with brain cancer. His personal and professional experience has allowed him to see both sides of patient care and develop close relationships with his patients.
Dr. Khan's broad training ranges from his degree at Shifa College of Medicine in Islamabad to internship and residency at the UT Houston/MD Anderson Cancer Center, to fellowships in hematology and oncology at UC Irvine Medical Center. He's done research in stem cell transplant and breast cancer and has presented at various national medical conferences.
Dr. Khan, who sees patients at City of Hope's Colton facility, enjoys being a community physician with ties to a major cancer center, enabling him to give patients “excellent care close to home.”
- 2016 - Present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Colton, CA
- 2010 - 2013, Premier Hospitalist Group of California, Internal Medicine/Hospitalist
- 2005, Shifa College of Medicine/Bahria University,Islamabad, Pakistan, Bachelor of Medicine & Bachelor of Surgery (MBBS)
- 2013 - 2016, University of California Irvine, Irvine CA, Fellowship, Hematology/Oncology
- 2007 - 2010, University of Texas at Houston, Houston, TX, Internship and Residency, Internal Medicine
- American Board of Internal Medicine
- American Board of Internal Medicine- Hematology
- American Board of Internal Medicine- Medical Oncology
Yang W, Tran P, Khan Z, Rezk S, O’Brien S. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL. Leuk Lymphoma. 2016 Oct 24:1-4. Cited in PubMed; PMID: 27774846
Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 2015 May; 88(2):231-4. Cited in PubMed; PMID: 25736571
Rubab S, Mustafa F, Imran M, Haq T, Khan ZU, Zubair M, Rasool TU, Ajmal M, Qamar R. Prevalence of Hepatitis C Virus in Urban Ghettos of Twin Cities. Pakistan J. Zool., vol. 44(4), pp. 937-943, 2012
Qazilbash MH, Amjad Al, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, DeLima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant. 2009 Oct; 15(10): 1265-70. Cited in PubMed; PMID: 19747634
Parikh GH, Amjad Al, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7): 812-6. Cited in PubMed; PMID: 19539212
Khan ZU, Saliba R, Qureshi S, Hosing C, Giralt S, DeLima MJ, Yusuf S, Popat U, Champlin R, Qazilbash MH. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Blood. 2008 Nov; 112(11): 1135
- American Society of Clinical Oncology
- American Society of Hematology